The study assessed the cost-effectiveness of FreeStyle Libre real-time continuous glucose monitoring (rtCGM) against self-monitoring of blood glucose (SMBG). Adults had type 2 diabetes above glucose target, on basal insulin plus an SGLT-2 inhibitor and/or GLP-1 agonist. Trial EQ-5D-5L and resource-use data fed the IQVIA CORE Diabetes Model for lifetime projections from the UK NHS perspective. At 32 weeks there was no significant difference in QALYs (-0.015) or costs (£254). Over a lifetime, rtCGM gained 0.730 QALYs for £4,341 more, an ICER of £5,943 per QALY. The lifetime result rests on modelled HbA1c benefits, with at least 4 years of maintained benefit needed for cost-effectiveness.
Why it is interesting: Within the trial, QALYs and costs did not differ significantly, yet the lifetime model gave a low cost per QALY. The result depends on the HbA1c benefit being assumed to last at least 4 years.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.